Neurodon LLC Profile last edited on: 10/2/2019
CAGE: 82D57
UEI: TH7KCXJBEJ35
Business Identifier: Biopharmaceuticals for small molecules that restore cellular homeostasis 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 01
County: Lake
Congr. District: 01
County: Lake
Public Profile
Neurodon LLC is a biopharmaceutical company focused on novel, clinically-relevant pathway with advanced programs in 4 sepcific therapeutic areas: medicines to improve memory and cognition in Alzheimer's Disease; therapeutics to cure akinesia in Parkinson't Disease; compounds for Diabetes IND-enabling studies; and molecules showing efficacy for stroke and traumatic brain injury. The company has expertise in small molecules that restore cellular homeostasis.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2023 | 1 | NIH | $286,348 | |
| Project Title: Preclinical evaluation of SERCA2 allosteric activators for pancreatic ?-cell protection in diabetes | ||||
| 2023 | 2 | NIH | $3,438,588 | |
| Project Title: Optimization of Small Molecule SERCA2B Activators to Inhibit Neuron Loss in Alzheimer's Disease | ||||
Key People / Management
Russell Dahl -- CEO and founder of Neurodon
Colleen Mauger -- Research Coordinator
Colleen Mauger -- Research Coordinator
Company News
There are no news available.
